CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
USA - NASDAQ:CCRN - US2274831047 - Common Stock
13.54 USD
-0.12 (-0.88%)
13.54 USD
0 (0%)
Taking everything into account, CCRN scores 5 out of 10 in our fundamental rating. CCRN was compared to 101 industry peers in the Health Care Providers & Services industry. CCRN has an excellent financial health rating, but there are some minor concerns on its profitability. CCRN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
CCRN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CCRN reported negative net income in multiple years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
CCRN's Return On Assets of -1.51% is in line compared to the rest of the industry. CCRN outperforms 42.57% of its industry peers.
CCRN has a Return On Equity of -2.02%. This is comparable to the rest of the industry: CCRN outperforms 49.51% of its industry peers.
CCRN's Return On Invested Capital of 1.44% is in line compared to the rest of the industry. CCRN outperforms 43.56% of its industry peers.
CCRN had an Average Return On Invested Capital over the past 3 years of 15.05%. This is significantly above the industry average of 9.19%.
The last Return On Invested Capital (1.44%) for CCRN is well below the 3 year average (15.05%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROIC | 1.44% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
1.3 Margins
The Operating Margin of CCRN (0.78%) is comparable to the rest of the industry.
CCRN's Operating Margin has declined in the last couple of years.
CCRN has a Gross Margin (20.19%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CCRN is creating some value.
Compared to 1 year ago, CCRN has less shares outstanding
CCRN has less shares outstanding than it did 5 years ago.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.08 indicates that CCRN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.08, CCRN belongs to the top of the industry, outperforming 83.17% of the companies in the same industry.
There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.08 |
ROIC/WACC0.16
WACC8.78%
2.3 Liquidity
CCRN has a Current Ratio of 3.21. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
CCRN has a Current ratio of 3.21. This is amongst the best in the industry. CCRN outperforms 85.15% of its industry peers.
A Quick Ratio of 3.21 indicates that CCRN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.21, CCRN belongs to the best of the industry, outperforming 86.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -78.35% in the last year.
CCRN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.57% yearly.
Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -24.30% in the last year.
Measured over the past years, CCRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
3.2 Future
Based on estimates for the next years, CCRN will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.16% on average per year.
CCRN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.63% yearly.
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 64.48, which means the current valuation is very expensive for CCRN.
CCRN's Price/Earnings is on the same level as the industry average.
CCRN is valuated expensively when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 48.27 indicates a quite expensive valuation of CCRN.
CCRN's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.86. CCRN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.48 | ||
| Fwd PE | 48.27 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCRN is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCRN indicates a rather cheap valuation: CCRN is cheaper than 81.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.01 | ||
| EV/EBITDA | 13.39 |
4.3 Compensation for Growth
A cheap valuation may be justified as CCRN's earnings are expected to decrease with -16.16% in the coming years.
PEG (NY)N/A
PEG (5Y)2.62
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.54
-0.12 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.48%
Inst Owner Change-1.99%
Ins Owners5.37%
Ins Owner Change-0.22%
Market Cap443.57M
Analysts52.31
Price Target18.44 (36.19%)
Short Float %7.3%
Short Ratio7.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.4%
Min EPS beat(2)-118.38%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-39.17%
Min EPS beat(4)-118.38%
Max EPS beat(4)22.23%
EPS beat(8)4
Avg EPS beat(8)-22%
EPS beat(12)8
Avg EPS beat(12)-10.41%
EPS beat(16)12
Avg EPS beat(16)-0.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.65%
Min Revenue beat(2)-7.46%
Max Revenue beat(2)-5.84%
Revenue beat(4)0
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-7.46%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)7
Avg Revenue beat(16)0.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.48 | ||
| Fwd PE | 48.27 | ||
| P/S | 0.37 | ||
| P/FCF | 13.01 | ||
| P/OCF | 10.66 | ||
| P/B | 1.08 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 13.39 |
EPS(TTM)0.21
EY1.55%
EPS(NY)0.28
Fwd EY2.07%
FCF(TTM)1.04
FCFY7.69%
OCF(TTM)1.27
OCFY9.38%
SpS36.4
BVpS12.58
TBVpS7.31
PEG (NY)N/A
PEG (5Y)2.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROCE | 2.04% | ||
| ROIC | 1.44% | ||
| ROICexc | 1.75% | ||
| ROICexgc | 3.24% | ||
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% | ||
| FCFM | 2.86% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
ROICexc(3y)15.28%
ROICexc(5y)13.73%
ROICexgc(3y)22.9%
ROICexgc(5y)20.79%
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3Y-75.41%
ROICexcg growth 5Y-32.32%
ROICexc growth 3Y-77.25%
ROICexc growth 5Y-30.83%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score5
Asset Turnover2.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 42.39% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.74% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 | ||
| Altman-Z | 5.08 |
F-Score5
WACC8.78%
ROIC/WACC0.16
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
EBIT growth 1Y-69.02%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year635.23%
EBIT Next 3Y126.18%
EBIT Next 5YN/A
FCF growth 1Y-88.57%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-86.63%
OCF growth 3YN/A
OCF growth 5Y85.29%